NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Has “Buy” Rating Reiterated at Mizuho Securities
Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock. The analyst noted the FDA’s recently reported date of the Advisory Committee for Aerie Pharmaceutical's Rhopressa to take place on October 13, 2017. This meeting is considered routine to take place before approval of a new product, specifically a new molecular entity. The analyst also noted another key date to remember in regards to the FDA meeting: October 11, the anticipated date that the FDA will release the background information on Rhopressa. This document typically offers a…
